In search of estrogen alternatives for the brain

Hormones, Cognition and Dementia: State of The Art and Emergent Therapeutic Strategies

Volumn , Issue , 2009, Pages 93-100

  Zhao, Liqin ^a   Brinton, Roberta Diaz ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053260556     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511635700.011     Document Type: Chapter

References (71)

1. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2651-62.
2. Shumaker SA, Legault C, Kuller LH, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004; 291:2947-58.
3. Espeland MA, Rapp SR, Shumaker SA, et al. Conjugated equine estrogens and global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study. JAMA. 2004; 291: 2959-68.
4. Rapp SR, Espeland MA, Shumaker SA, et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA. 2003; 289:2663-72
5. American Academy of Neurology. Estrogen use before 65 linked to reduced risk of Alzheimer’s disease. Available at: http://www.aan.com/press/indexcfm?fuseaction=releaseview&release=471. Accessed July 3, 2008.
6. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med. 2007; 356:2591-602.
7. Rossouw JE, Prentice RL, Manson JE, et al Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007; 297:1465-77.
8. Zandi PP, Anthony JC, Hayden KM, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County Study. Neurology. 2002; 59:880-6.
9. MacLennan AH, Henderson VW, Paine BJ, et al. Hormone therapy, timing of initiation, and cognition in women aged older than 60 years: the REMEMBER pilot study. Menopause. 2006; 13:28-36.
10. Brinton RD. Estrogen therapy for prevention of Alzheimer’s disease not for rehabilitation following onset of disease: the healthy cell bias of estrogen action. In Baudry M, Bi R, Schreiber SS, eds. Synaptic Plasticity: Basic Mechanisms to Clinical Applications. New York: Taylor & Francis Group, 2004, pp. 131-57.
11. Brinton RD. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci. 2005; 1052:57-74.
12. Prewitt AK, Wilson ME. Changes in estrogen receptor- alpha mRNA in the mouse cortex during development. Brain Res. 2007; 1134:62-9.
13. Zhang JQ, Cai WQ, Zhou de S, et al. Distribution and differences of estrogen receptor beta immunoreactivity in the brain of adult male and female rats. Brain Res. 2002; 935:73-80.
14. Yaden BC, Krishnan GV, Bryant HU, et al. Discovery and characterization of selective ERbeta agonist. The Endocrine Society 87th Annual Meeting, San Diego. 2005, pp. 3-295.
15. Corrieri L, Della Seta D, Canoine V, etal. Developmental exposure to xenoestrogen enhances spatial learning in male rats. Horm Behav. 2007; 51:620-5.
16. Toung TJ, Traystman RJ, Hurn PD. Estrogen- mediated neuroprotection after experimental stroke in male rats. Stroke. 1998; 29:1666-70.
17. McCullough LD, Alkayed NJ, Traystman RJ, et al. Postischemic estrogen reduces hypoperfusion and secondary ischemia after experimental stroke. Stroke. 2001; 32:796-802.
18. Hogervorst E, De Jager C, Budge M, et al. Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology. 2004; 29:405-21.
19. Cherrier MM, Matsumoto AM, Amory JK, et al. The role of aromatization in testosterone supplementation: effects on cognition in older men. Neurology. 2005; 64:290-6.
20. Beer TM, Bland LB, Bussiere JR, et al. Testosterone loss and estradiol administration modify memory in men. J Urol. 2006; 175:130-5.
21. Sayed Y, Taxel P. The use of estrogen therapy in men. Curr Opin Pharmacol. 2003; 3:650-4.
22. Zhao L, O’Neill K, Brinton RD. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res Brain Res Rev. 2005; 49: 472-93.
23. Taxel P, Stevens MC, Trahiotis M, et al. The effect of short-term estradiol therapy on cognitive function in older men receiving hormonal suppression therapy for prostate cancer. J Am Geriatr Soc. 2004; 52:269-73.
24. Ravdin PM, Cronin KA, Howlader N, et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356:1670-4.
25. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA. 2003; 289: 2673-84.
26. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women’s Health Initiative. Circulation. 2006; 113:2425-34.
27. Littleton-Kearney MT, Ostrowski NL, Cox DA, et al. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev. 2002; 8:309-30.
28. Dhandapani KM, Brann DW. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol Reprod. 2002; 67:1379-85.
29. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease. Nat Rev Neurosci. 2002; 3:862-72.
30. Yaffe K, Krueger K, Sarkar S, et al. Cognitive function in postmenopausal women treated with raloxifene. NEngl J Med. 2001; 344:1207-13.
31. Yaffe K, Krueger K, Cummings SR, et al. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. Am J Psychiatry. 2005; 162:683-90.
32. Buckwalter JG, Geiger AM, Parsons TD, et al. Cognitive effects of short-term use of raloxifene: a randomized clinical trial. Int J Neurosci. 2007; 117: 1579-90.
33. Haskell SG, Richardson ED. The effect of raloxifene on cognitive function in postmenopausal women: a randomized clinical trial. Conn Med. 2004; 68:355-8.
34. Goekoop R, Duschek EJ, Knol DL, et al Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. Neuroimage. 2005; 25:63-75.
35. Goekoop R, Barkhof F, Duschek EJ, et al. Raloxifene treatment enhances brain activation during recognition of familiar items: a pharmacological fMRI study in healthy elderly males. Neuropsychopharmacology. 2006; 31:1508-18.
36. Zhao L, Jin C, Mao Z, et al. Design, synthesis, and estrogenic activity of a novel estrogen receptor modulator - a hybrid structure of 17beta-estradiol and vitamin E in hippocampal neurons. J Med Chem. 2007; 50:4471-81.
37. Zhao L, O’Neill K, Brinton RD. Estrogenic agonist activity of ICI 182,780 (Faslodex) in hippocampal neurons: implications for basic science understanding of estrogen signaling and development of estrogen modulators with a dual therapeutic profile. J Pharmacol Exp Ther. 2006; 319:1124-32.
38. Howell A, Osborne CK, Morris C, et al. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000; 89:817-25.
39. Zhao L, Brinton RD. Estrogen receptor beta as a therapeutic target for promotion of neurogenesis and prevention of neurodegeneration. Drug Dev Res. 2006; 66:103-17.
40. Zhao L, Brinton RD. Estrogen receptor alpha and beta differentially regulate intracellular Ca(2+) dynamics leading to ERK phosphorylation and estrogen neuroprotection in hippocampal neurons. Brain Res. 2007; 1172:48-59.
41. Zhao L, Wu T-W, Brinton RD. Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. Brain Res. 2004; 1010:22-34.
42. Simpkins JW, Yang SH, Sarkar SN, et al. Estrogen actions on mitochondria - physiological and pathological implications. Mol Cell Endocrinol. 2008; 290(1/2):51-9.
43. Simpkins JW, Dykens JA. Mitochondrial mechanisms of estrogen neuroprotection. Brain Res Rev. 2008; 57:421-30.
44. Nilsen J, Brinton RD. Mitochondria as therapeutic targets of estrogen action in the central nervous system. Curr Drug Targets CNS Neurol Disord. 2004; 3:297-313.
45. Wang L, Andersson S, Warner M, et al. Estrogen receptor (ER) beta knockout mice reveal a role for ERbeta in migration of cortical neurons in the developing brain. Proc Natl Acad Sci USA. 2003; 100:703-8.
46. Wang L, Andersson S, Warner M, et al. Morphological abnormalities in the brains of estrogen receptor beta knockout mice. Proc Natl Acad Sci USA. 2001; 98:2792-6.
47. Rissman EF, Heck AL, Leonard JE, et al. Disruption of estrogen receptor beta gene impairs spatial learning in female mice. Proc Natl Acad Sci USA. 2002; 99: 3996-4001.
48. Day M, Sung A, Logue S, et al. Beta estrogen receptor knockout (BERKO) mice present attenuated hippocampal CA1 long-term potentiation and related memory deficits in contextual fear conditioning. Behav Brain Res. 2005; 164:128-31.
49. Liu F, Day M, Muniz LC, et al. Activation of estrogen receptor-beta regulates hippocampal synaptic plasticity and improves memory. Nat Neurosci. 2008; 11:334-43.
50. Fan X, Warner M, Gustafsson JA. Estrogen receptor beta expression in the embryonic brain regulates development of calretinin-immunoreactive GABAergic interneurons. Proc Natl Acad Sci USA. 2006; 103:19338-43.
51. Walf AA, Frye CA. Rapid and estrogen receptor beta mediated actions in the hippocampus mediate some functional effects of estrogen. Steroids. 2008; 73:997-1007.
52. Wang JM, Irwin RW, Brinton RD. Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc Natl Acad Sci USA. 2006; 103:16983-8.
53. Rice MM, La Croix AZ, Lampe JW, et al. Dietary soy isoflavone intake in older Japanese American women. Public Health Nutr. 2001; 4:943-52.
54. Maskarinec S. The effect of phytoestrogens on hot flashes. Nutrition Bytes. 2003; 9: Article 5
55. Ziegler RG. Phytoestrogens and breast cancer. Am J Clin Nutr. 2004; 79:183-4.
56. Henderson BE, Bernstein L. The international variation in breast cancer rates: an epidemiological assessment. Breast Cancer Res Treat. 1991; 18(Suppl 1): S11-7.
57. Goetzl MA, Van Veldhuizen PJ, Thrasher JB. Effects of soy phytoestrogens on the prostate. Prostate Cancer Prostatic Dis. 2007; 10:216-23.
58. de Kleijn MJ, van der Schouw YT, Wilson PW, et al. Intake of dietary phytoestrogens is low in postmenopausal women in the United States: the Framingham study. J Nutr. 2001; 131:1826-32.
59. Zhao L, Brinton RD. WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. Expert Rev Neurother. 2007; 7:1549-64
60. Zhao L, Chen Q, Brinton RD. Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. Exp Biol Med. 2002; 227:509-19.
61. Zhao L, Mao Z, Brinton RD. A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. Endocrinology. 2009; 150:770-83.
62. Setchell KD, Brown NM, Desai P, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr. 2001; 131(4 Suppl):1362S-75S.
63. Setchell KD, Borriello SP, Hulme P, et al. Nonsteroidal estrogens of dietary origin: possible roles in hormone-dependent disease. Am J Clin Nutr. 1984; 40:569-78.
64. Morito K, Hirose T, Kinjo J, et al. Interaction of phytoestrogens with estrogen receptors alpha and beta. Biol Pharm Bull. 2001; 24:351-6.
65. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol - a clue to the effectiveness of soy and its isoflavones. J Nutr. 2002; 132:3577-84.
66. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med. 2005; 230:155-70.
67. Frankenfeld CL, McTiernan A, Thomas WK, et al. Postmenopausal bone mineral density in relation to soy isoflavone-metabolizing phenotypes. Maturitas. 2006; 53:315-24.
68. Niculescu MD, Pop EA, Fischer LM, et al. Dietary isoflavones differentially induce gene expression changes in lymphocytes from postmenopausal women who form equol as compared with those who do not. J Nutr Biochem. 2007; 18:380-90.
69. Wu J, Oka J, Ezaki J, et al. Possible role of equol status in the effects of isoflavone on bone and fat mass in postmenopausal Japanese women: a double-blind, randomized, controlled trial. Menopause. 2007; 14:866-74.
70. Akaza H, Miyanaga N, Takashima N, et al. Comparisons of percent equol producers between prostate cancer patients and controls: case-controlled studies of isoflavones in Japanese, Korean and American residents. Jpn J Clin Oncol. 2004; 34:86-9.
71. Arai Y, Uehara M, Sato Y, et al. Comparison of isoflavones among dietary intake, plasma concentration and urinary excretion for accurate estimation of phytoestrogen intake. J Epidemiol. 2000; 10: 127-35.